The Journal of investigative dermatology · 2021
Efficacy and Safety of Tacrolimus 0.1% for the Treatment of Facial Vitiligo: A Multicenter Randomized, Double-Blinded, Vehicle-Controlled Study.
СтатьяМногоцентровое исследованиеРандомизированное исследованиеПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Seneschal Julien, Duplaine Alexandra, Maillard Hervé, Passeron Thierry, Andreu Nicolas, Lassalle Régis, Favary Clélia, Droitcourt Catherine, Taïeb Alain, Ezzedine Khaled
Аннотация
BACKGROUND: Topical calcineurin inhibitors are used off label in the treatment of vitiligo, and there is a lack of placebo-controlled, blinded studies to support their use.
OBJECTIVE: This study aimed to compare the efficacy of tacrolimus 0.1% ointment with that of the vehicle for repigmentation in adult patients with facial vitiligo.
DESIGN: This study was a 24-week multicenter randomized parallel double-blind study with a 24-week post-treatment follow-up extension.
POPULATION: Participants included were adult patients with recent facial vitiligo target lesions (<2 years) without changes in pigmentation or size over the previous 3 months.
INTERVENTION: Patients received either tacrolimus 0.1% ointment or vehicle twice daily.
MAIN OUTCOMES AND MEASURES: The primary outcome was a therapeutic success, defined as a change ≥75% in the repigmentation of the target lesion between baseline and week 24, measured by ImageJ software. Secondary outcome measures were a variation of the physicians' global assessment scores and patients' satisfaction scores, safety data, and the rate of relapse at week 48.
RESULTS: A total of 42 patients were included. Therapeutic success was achieved in 65% of tacrolimus-treated patients versus 0% of vehicle-treated patients at week 24 (P < 0.0001). Only 40% of relapse was observed at 48 weeks.
CONCLUSIONS AND RELEVANCE: Twice-daily tacrolimus 0.1% ointment showed superior efficacy to that of the vehicle through the 24 weeks of intervention and 24 weeks of follow-up in adult patients with facial vitiligo.
TRIAL REGISTRATION: This study was registered at ClinicalTrials.gov (identifier: NCT02466997).
OBJECTIVE: This study aimed to compare the efficacy of tacrolimus 0.1% ointment with that of the vehicle for repigmentation in adult patients with facial vitiligo.
DESIGN: This study was a 24-week multicenter randomized parallel double-blind study with a 24-week post-treatment follow-up extension.
POPULATION: Participants included were adult patients with recent facial vitiligo target lesions (<2 years) without changes in pigmentation or size over the previous 3 months.
INTERVENTION: Patients received either tacrolimus 0.1% ointment or vehicle twice daily.
MAIN OUTCOMES AND MEASURES: The primary outcome was a therapeutic success, defined as a change ≥75% in the repigmentation of the target lesion between baseline and week 24, measured by ImageJ software. Secondary outcome measures were a variation of the physicians' global assessment scores and patients' satisfaction scores, safety data, and the rate of relapse at week 48.
RESULTS: A total of 42 patients were included. Therapeutic success was achieved in 65% of tacrolimus-treated patients versus 0% of vehicle-treated patients at week 24 (P < 0.0001). Only 40% of relapse was observed at 48 weeks.
CONCLUSIONS AND RELEVANCE: Twice-daily tacrolimus 0.1% ointment showed superior efficacy to that of the vehicle through the 24 weeks of intervention and 24 weeks of follow-up in adult patients with facial vitiligo.
TRIAL REGISTRATION: This study was registered at ClinicalTrials.gov (identifier: NCT02466997).